#term ID	term description	observed gene count	background gene count	strength	signal	false discovery rate	matching proteins in your network (IDs)	matching proteins in your network (labels)
WP5078	T cell modulation in pancreatic cancer	6	45	1.42	1.04	0.00016	9606.ENSP00000312002,9606.ENSP00000370989,9606.ENSP00000380855,9606.ENSP00000385675,9606.ENSP00000402060,9606.ENSP00000412237	HAVCR2,CD274,PDCD1LG2,IL6,PVR,IL10
WP4891	COVID-19 adverse outcome pathway	4	15	1.72	0.89	0.00084	9606.ENSP00000306512,9606.ENSP00000385675,9606.ENSP00000389326,9606.ENSP00000412237	CXCL8,IL6,ACE2,IL10
WP4217	Ebola virus infection in host	7	129	1.03	0.72	0.0014	9606.ENSP00000285735,9606.ENSP00000295408,9606.ENSP00000301178,9606.ENSP00000312002,9606.ENSP00000331831,9606.ENSP00000415283,9606.ENSP00000497069	RHOC,MERTK,AXL,HAVCR2,GAS6,ICAM2,IGF1R
WP4172	PI3K-Akt signaling pathway	10	336	0.77	0.62	0.0018	9606.ENSP00000261405,9606.ENSP00000327513,9606.ENSP00000351209,9606.ENSP00000376943,9606.ENSP00000378517,9606.ENSP00000379111,9606.ENSP00000384849,9606.ENSP00000385675,9606.ENSP00000495951,9606.ENSP00000497069	VWF,CSF1,EPHA2,BCL2L11,SPP1,IL4R,CDKN1A,IL6,KITLG,IGF1R
WP4396	Nonalcoholic fatty liver disease	7	154	0.96	0.68	0.0018	9606.ENSP00000162749,9606.ENSP00000258424,9606.ENSP00000274137,9606.ENSP00000294728,9606.ENSP00000306512,9606.ENSP00000376943,9606.ENSP00000385675	TNFRSF1A,COX5B,NDUFS6,VCAM1,CXCL8,BCL2L11,IL6
WP4754	IL-18 signaling pathway	9	271	0.82	0.64	0.0018	9606.ENSP00000162749,9606.ENSP00000295927,9606.ENSP00000306512,9606.ENSP00000356505,9606.ENSP00000378517,9606.ENSP00000385675,9606.ENSP00000412237,9606.ENSP00000434717,9606.ENSP00000495951	TNFRSF1A,PTX3,CXCL8,NCF2,SPP1,IL6,IL10,IL18BP,KITLG
WP5087	Malignant pleural mesothelioma	11	434	0.7	0.6	0.0018	9606.ENSP00000327513,9606.ENSP00000351209,9606.ENSP00000361850,9606.ENSP00000368710,9606.ENSP00000370989,9606.ENSP00000384849,9606.ENSP00000385451,9606.ENSP00000385675,9606.ENSP00000412237,9606.ENSP00000495951,9606.ENSP00000497069	CSF1,EPHA2,PLAU,RASSF2,CD274,CDKN1A,MDK,IL6,IL10,KITLG,IGF1R
WP5222	2q13 copy number variation syndrome	5	60	1.22	0.74	0.0018	9606.ENSP00000295408,9606.ENSP00000327513,9606.ENSP00000331831,9606.ENSP00000376943,9606.ENSP00000385675	MERTK,CSF1,GAS6,BCL2L11,IL6
WP3624	Lung fibrosis	5	63	1.2	0.73	0.0019	9606.ENSP00000295927,9606.ENSP00000306512,9606.ENSP00000361850,9606.ENSP00000378517,9606.ENSP00000385675	PTX3,CXCL8,PLAU,SPP1,IL6
WP474	Endochondral ossification	5	62	1.21	0.73	0.0019	9606.ENSP00000283147,9606.ENSP00000295113,9606.ENSP00000361850,9606.ENSP00000378517,9606.ENSP00000497069	BMP6,FRZB,PLAU,SPP1,IGF1R
WP4808	Endochondral ossification with skeletal dysplasias	5	62	1.21	0.73	0.0019	9606.ENSP00000283147,9606.ENSP00000295113,9606.ENSP00000361850,9606.ENSP00000378517,9606.ENSP00000497069	BMP6,FRZB,PLAU,SPP1,IGF1R
WP5039	SARS-CoV-2 innate immunity evasion and cell-specific immune response	5	66	1.18	0.73	0.0019	9606.ENSP00000306512,9606.ENSP00000312002,9606.ENSP00000385675,9606.ENSP00000389326,9606.ENSP00000412237	CXCL8,HAVCR2,IL6,ACE2,IL10
WP5322	CKAP4 signaling pathway map	6	114	1.02	0.69	0.0019	9606.ENSP00000009530,9606.ENSP00000162749,9606.ENSP00000361850,9606.ENSP00000370542,9606.ENSP00000376943,9606.ENSP00000385675	CD74,TNFRSF1A,PLAU,SDC1,BCL2L11,IL6
WP3617	Photodynamic therapy-induced NF-kB survival signaling	4	34	1.37	0.75	0.0021	9606.ENSP00000162749,9606.ENSP00000294728,9606.ENSP00000306512,9606.ENSP00000385675	TNFRSF1A,VCAM1,CXCL8,IL6
WP4329	miRNA role in immune response in sepsis	4	37	1.33	0.71	0.0027	9606.ENSP00000294728,9606.ENSP00000306512,9606.ENSP00000385675,9606.ENSP00000412237	VCAM1,CXCL8,IL6,IL10
WP4806	EGFR tyrosine kinase inhibitor resistance	5	83	1.08	0.64	0.0039	9606.ENSP00000301178,9606.ENSP00000331831,9606.ENSP00000376943,9606.ENSP00000385675,9606.ENSP00000497069	AXL,GAS6,BCL2L11,IL6,IGF1R
WP3646	Hepatitis C and hepatocellular carcinoma	4	48	1.22	0.61	0.0060	9606.ENSP00000295113,9606.ENSP00000306512,9606.ENSP00000384849,9606.ENSP00000385675	FRZB,CXCL8,CDKN1A,IL6
WP4493	Cells and molecules involved in local acute inflammatory response 	3	17	1.55	0.64	0.0060	9606.ENSP00000294728,9606.ENSP00000306512,9606.ENSP00000385675	VCAM1,CXCL8,IL6
WP3611	Photodynamic therapy-induced AP-1 survival signaling	4	50	1.2	0.6	0.0063	9606.ENSP00000162749,9606.ENSP00000376943,9606.ENSP00000384849,9606.ENSP00000385675	TNFRSF1A,BCL2L11,CDKN1A,IL6
WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway	8	301	0.72	0.51	0.0063	9606.ENSP00000261405,9606.ENSP00000327513,9606.ENSP00000351209,9606.ENSP00000378517,9606.ENSP00000379111,9606.ENSP00000384849,9606.ENSP00000495951,9606.ENSP00000497069	VWF,CSF1,EPHA2,SPP1,IL4R,CDKN1A,KITLG,IGF1R
WP4970	Galanin receptor pathway	3	20	1.47	0.61	0.0074	9606.ENSP00000376943,9606.ENSP00000384849,9606.ENSP00000385675	BCL2L11,CDKN1A,IL6
WP2877	Vitamin D receptor pathway	6	183	0.81	0.47	0.0133	9606.ENSP00000275525,9606.ENSP00000283147,9606.ENSP00000340983,9606.ENSP00000350896,9606.ENSP00000378517,9606.ENSP00000384849	IGFBP1,BMP6,LRRC25,EPHB4,SPP1,CDKN1A
WP530	Cytokines and inflammatory response	3	26	1.36	0.53	0.0137	9606.ENSP00000327513,9606.ENSP00000385675,9606.ENSP00000412237	CSF1,IL6,IL10
WP5095	Overview of proinflammatory and profibrotic mediators	5	126	0.9	0.46	0.0166	9606.ENSP00000306512,9606.ENSP00000327513,9606.ENSP00000378517,9606.ENSP00000385675,9606.ENSP00000412237	CXCL8,CSF1,SPP1,IL6,IL10
WP453	Inflammatory response pathway	3	30	1.3	0.49	0.0185	9606.ENSP00000162749,9606.ENSP00000365435,9606.ENSP00000379111	TNFRSF1A,TNFRSF1B,IL4R
WP5113	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway	3	31	1.28	0.48	0.0195	9606.ENSP00000306512,9606.ENSP00000385675,9606.ENSP00000389326	CXCL8,IL6,ACE2
WP5088	Prostaglandin signaling	3	32	1.27	0.48	0.0204	9606.ENSP00000306512,9606.ENSP00000327513,9606.ENSP00000385675	CXCL8,CSF1,IL6
WP5083	Neuroinflammation and glutamatergic signaling	5	140	0.85	0.43	0.0226	9606.ENSP00000162749,9606.ENSP00000365435,9606.ENSP00000379111,9606.ENSP00000385675,9606.ENSP00000412237	TNFRSF1A,TNFRSF1B,IL4R,IL6,IL10
WP5115	Network map of SARS-CoV-2 signaling pathway	6	218	0.74	0.4	0.0247	9606.ENSP00000302935,9606.ENSP00000306512,9606.ENSP00000338171,9606.ENSP00000385675,9606.ENSP00000389326,9606.ENSP00000412237	IL16,CXCL8,SKAP1,IL6,ACE2,IL10
WP254	Apoptosis	4	83	0.98	0.43	0.0248	9606.ENSP00000162749,9606.ENSP00000365435,9606.ENSP00000376943,9606.ENSP00000497069	TNFRSF1A,TNFRSF1B,BCL2L11,IGF1R
WP5285	Immune infiltration in pancreatic cancer	3	38	1.2	0.44	0.0284	9606.ENSP00000306512,9606.ENSP00000385675,9606.ENSP00000412237	CXCL8,IL6,IL10
WP3941	Oxidative damage response	3	39	1.18	0.43	0.0295	9606.ENSP00000363773,9606.ENSP00000365435,9606.ENSP00000384849	C1QA,TNFRSF1B,CDKN1A
WP2806	Complement system	4	96	0.92	0.38	0.0373	9606.ENSP00000295927,9606.ENSP00000378517,9606.ENSP00000415283,9606.ENSP00000436607	PTX3,SPP1,ICAM2,ADM
WP5198	Inflammatory bowel disease signaling	3	43	1.14	0.4	0.0373	9606.ENSP00000379111,9606.ENSP00000385675,9606.ENSP00000412237	IL4R,IL6,IL10
WP5166	Glyoxylate metabolism	2	11	1.56	0.41	0.0416	9606.ENSP00000302620,9606.ENSP00000368066	AGXT,HAO1
WP2203	Thymic stromal lymphopoietin (TSLP) signaling pathway	3	47	1.1	0.38	0.0435	9606.ENSP00000306512,9606.ENSP00000385675,9606.ENSP00000462468	CXCL8,IL6,YES1
WP2848	Pluripotent stem cell differentiation pathway	3	47	1.1	0.38	0.0435	9606.ENSP00000327513,9606.ENSP00000385675,9606.ENSP00000495951	CSF1,IL6,KITLG
WP4495	IL-10 anti-inflammatory signaling pathway 	2	12	1.52	0.4	0.0445	9606.ENSP00000385675,9606.ENSP00000412237	IL6,IL10
WP5090	Complement system in neuronal development and plasticity	4	105	0.88	0.36	0.0445	9606.ENSP00000295408,9606.ENSP00000301178,9606.ENSP00000331831,9606.ENSP00000363773	MERTK,AXL,GAS6,C1QA
WP1434	Osteopontin signaling	2	13	1.49	0.38	0.0486	9606.ENSP00000361850,9606.ENSP00000378517	PLAU,SPP1
